PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|July 6, 2015
Sartorius Stedim Biotech Acquires Cellca
Author(s)Pharmaceutical Technology Editors
According to Sartorius Stedim Biotech, this acquisition expands its service offering for process development.
Advertisement
Sartorius Stedim Biotech, an international supplier for the pharma and biotech industries,
Cellca was founded in 2005 and has approximately 30 employees. The company’s major customers are from the biopharmaceutical industry, including biosimilar firms that do not or only partly conduct their process development in their in-house facilities. Cellca generated sales revenue of approximately EUR6 million in 2014.
According to Sartorius Stedim Biotech, this acquisition expands its service offering for process development in addition to its two recent acquisitions of BioOutsource and TAP Biosystems.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement